Lenvaxen (lenvatinib) is a kinase inhibitor primarily used for treating specific types of cancer, most notably radioactive iodine-refractory differentiated thyroid cancer.
Detailed Use of Lenvaxen 4mg
Lenvaxen, containing the active ingredient lenvatinib, is indicated for the treatment of:
- Differentiated Thyroid Cancer (DTC): Specifically, it's used in patients whose DTC is locally recurrent or metastatic, progressive, and no longer responds to radioactive iodine treatment.
How Lenvaxen Works
Lenvatinib is a kinase inhibitor. Kinases are enzymes that play a crucial role in cell growth and proliferation. By blocking these enzymes, lenvatinib can help slow down or stop the growth of cancer cells and the formation of new blood vessels that feed the tumor. This action is vital in managing progressive, treatment-resistant thyroid cancers.
Important Considerations
- Lenvaxen treatment should be initiated and supervised by a qualified oncologist.
- Dosage (including the 4mg strength) and treatment duration depend on the specific cancer type, patient characteristics, and response to therapy.
- Lenvaxen can have significant side effects, and patients should be closely monitored during treatment.
